191 results
Page 4 of 10
8-K
EX-1.1
umq clrywshuatsmnfin
27 Nov 20
Hepion Pharmaceuticals Prices Public Offering
1:48pm
424B4
8w7rjt5j3p6 8s1
25 Nov 20
Prospectus supplement with pricing info
4:28pm
8-K
EX-99.1
ekv7c
18 Nov 20
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation of Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
8:29am
8-K
EX-99.1
0n4 ogifwi
12 Nov 20
Hepion Pharmaceuticals to Present at The Liver Meeting Digital ExperienceTM 2020
9:33am
8-K
EX-99.1
quaprpj ob
10 Nov 20
Hepion Pharmaceuticals Completes First Cohort Enrollment in Phase 2a 'AMBITION' Clinical Trial
10:33am
8-K
EX-99.1
mud28
27 Oct 20
Other Events
9:45am
8-K
EX-99.1
lvmhb7y9h8w1uj
5 Oct 20
Announces Creation of Clinical Pharmacology Analytics Team
9:06am
8-K
EX-99.1
4ii0j68w9 ffjgsxc
17 Sep 20
Other Events
12:40pm
8-K
EX-99.1
k84232vr26w
1 Sep 20
Hepion Pharmaceuticals Completes Final Dosing in Phase 1b Multiple Ascending Dose Study of CRV431
1:27pm
8-K
EX-99.1
ucgqenv cyonoj
27 Aug 20
Other Events
11:19am
8-K
EX-99.1
yjy3212t by
12 Aug 20
Hepion Pharmaceuticals Announces Publication of Preclinical Study Evaluating CRV431’s Antiviral Properties
8:46am
8-K
EX-99.1
ce7hwjabs97o fknsji
5 Aug 20
Hepion Pharmaceuticals Announces First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial
9:18am
8-K
EX-99.1
k81 ywdqr
7 Jul 20
Hepion Pharmaceuticals Announces Preclinical Data Supporting Novel Two-Pronged Approach to Treating COVID-19 with CRV431
8:26am